Premium
Management of imatinib‐related exacerbation of psoriasis in a patient with a gastrointestinal stromal tumour
Author(s) -
Cheng Haiying,
Geist David E,
Piperdi May,
Virk Renu,
Piperdi Bilal
Publication year - 2009
Publication title -
australasian journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.67
H-Index - 53
eISSN - 1440-0960
pISSN - 0004-8380
DOI - 10.1111/j.1440-0960.2008.00495.x
Subject(s) - medicine , psoriasis , imatinib , methotrexate , exacerbation , gist , imatinib mesylate , dermatology , stromal cell , myeloid leukemia
SUMMARY A 62‐year‐old woman with a pre‐existing psoriasis was treated with oral imatinib (400 mg/day) for a metastatic gastrointestinal stromal tumour. Within 4 weeks of starting therapy, she developed a guttate psoriasis flare. The eruption markedly improved within 2 weeks following cessation of imatinib. However, it recurred when imatinib was recommenced. She has been able to continue on imatinib (400 mg/day) with low‐dose oral methotrexate (12.5 mg/week) controlling the psoriasis.